类风湿关节炎.pptVIP

Comments: The proportion of patients attaining an ACR20 response at Weeks 4, 8, 12, 16, 20 and 24 was an exploratory end point. Response rates were similar across the placebo plus MTX and rituximab plus MTX groups at Week 4. This is probably due to the glucocorticoids received by all patients over the first 2 weeks of treatment. After Week 4, fewer patients in the placebo plus MTX group demonstrated an ACR20 response, whereas the proportion of ACR20 responders was increased in the rituximab plus MTX group. By Week 8, there was a statistically significant separation in ACR20 response between t